Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Non-Current Assets (2024 - 2025)

Historic Non-Current Assets for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $36.4 million.

  • Prelude Therapeutics' Non-Current Assets fell 1079.52% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.9 million, marking a year-over-year change of. This contributed to the annual value of $39.6 million for FY2024, which is N/A changed from last year.
  • Per Prelude Therapeutics' latest filing, its Non-Current Assets stood at $36.4 million for Q3 2025, which was down 1079.52% from $38.0 million recorded in Q2 2025.
  • In the past 5 years, Prelude Therapeutics' Non-Current Assets registered a high of $41.7 million during Q1 2024, and its lowest value of $36.4 million during Q3 2025.